Symbols / NRXP $2.26 +2.50% NRx Pharmaceuticals, Inc.
NRXP Chart
About
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 74.57M |
| Enterprise Value | 65.51M | Income | -28.62M | Sales | 1.23M |
| Book/sh | -0.50 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 29 | IPO | — |
| P/E | — | Forward P/E | 17.35 | PEG | — |
| P/S | 60.87 | P/B | -4.48 | P/C | — |
| EV/EBITDA | -4.06 | EV/Sales | 53.48 | Quick Ratio | 0.28 |
| Current Ratio | 0.31 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.34 | EPS next Y | 0.13 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-15 | ROA | -121.85% |
| ROE | — | ROIC | — | Gross Margin | 58.78% |
| Oper. Margin | -4.67% | Profit Margin | 0.00% | Shs Outstand | 33.07M |
| Shs Float | 24.24M | Short Float | 9.14% | Short Ratio | 4.91 |
| Short Interest | — | 52W High | 3.84 | 52W Low | 1.58 |
| Beta | 1.83 | Avg Volume | 1.05M | Volume | 555.48K |
| Target Price | $38.00 | Recom | Strong_buy | Prev Close | $2.20 |
| Price | $2.25 | Change | 2.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.00
Mean price target
2. Current target
$2.25
Latest analyst target
3. DCF / Fair value
$-0.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.25
Low
$25.00
High
$48.00
Mean
$38.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-24 | reit | BTIG | Buy → Buy | $25 |
| 2026-03-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-16 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-03 | main | HC Wainwright & Co. | Buy → Buy | $45 |
| 2026-02-18 | reit | BTIG | Buy → Buy | $25 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-15 | reit | BTIG | Buy → Buy | $25 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-02 | main | Ascendiant Capital | Buy → Buy | $48 |
| 2025-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-03 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-12-03 | reit | BTIG | Buy → Buy | $25 |
| 2025-12-02 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-10 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-30 | main | Ascendiant Capital | Buy → Buy | $47 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
- FDA flags only minor label edits for U.S.-made ketamine amid backorders - Stock Titan Mon, 06 Apr 2026 11
- NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill hu, 02 Apr 2026 07
- H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com Fri, 03 Apr 2026 07
- NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates - Yahoo Finance Mon, 23 Mar 2026 07
- What date does NRx Pharmaceuticals's (NRXP) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research Mon, 23 Mar 2026 07
- Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits Wed, 14 Jan 2026 08
- NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus Mon, 16 Mar 2026 12
- NRx Pharma to outline drug pipeline and clinic network progress March 24 - Stock Titan hu, 19 Mar 2026 07
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 - GlobeNewswire ue, 24 Mar 2026 11
- NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill hu, 02 Apr 2026 07
- NRXP Sep 2026 5.000 call (NRXP260918C00005000) Stock Historical Prices & Data - ca.finance.yahoo.com hu, 02 Apr 2026 13
- Should I buy NRx Pharmaceuticals (NRXP) - Zacks Investment Research ue, 27 Jan 2026 08
- FDA review finds no issues with preservative-free ketamine, dropping additive - Stock Titan ue, 17 Mar 2026 07
- NRXP Apr 2026 2.500 put (NRXP260417P00002500) Interactive Stock Chart - ca.finance.yahoo.com Wed, 01 Apr 2026 17
- FDA lets ketamine depression drug seek approval without new trials - Stock Titan Mon, 16 Mar 2026 07
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.23
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
1.23
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.51
|
0.00
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
0.43
|
0.00
|
—
|
—
|
| Gross Profit |
|
0.72
|
0.00
|
—
|
—
|
| Operating Expense |
|
16.94
-8.42%
|
18.50
-32.93%
|
27.59
-37.78%
|
44.34
|
| Research And Development |
|
3.78
-39.07%
|
6.20
-53.64%
|
13.37
-21.47%
|
17.03
|
| Selling General And Administration |
|
13.06
-3.25%
|
13.50
-5.04%
|
14.22
-47.94%
|
27.31
|
| General And Administrative Expense |
|
13.06
-3.25%
|
13.50
-5.04%
|
14.22
-47.94%
|
27.31
|
| Other Gand A |
|
13.06
-3.25%
|
13.50
-5.04%
|
14.22
-47.94%
|
27.31
|
| Other Operating Expenses |
|
0.04
+103.00%
|
-1.20
-580.80%
|
0.25
|
—
|
| Total Expenses |
|
17.45
-5.69%
|
18.50
-32.93%
|
27.59
-37.78%
|
44.34
|
| Operating Income |
|
-16.22
+12.31%
|
-18.50
+32.93%
|
-27.59
+37.78%
|
-44.34
|
| Total Operating Income As Reported |
|
-16.22
+12.31%
|
-18.50
+33.53%
|
-27.84
+37.21%
|
-44.34
|
| EBITDA |
|
-27.81
-11.72%
|
-24.89
+17.10%
|
-30.02
+24.47%
|
-39.75
|
| Normalized EBITDA |
|
-26.97
-16.10%
|
-23.23
+22.02%
|
-29.80
+33.18%
|
-44.59
|
| Reconciled Depreciation |
|
0.14
+2760.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.00
|
| EBIT |
|
-27.95
-12.27%
|
-24.90
+17.10%
|
-30.03
+24.46%
|
-39.75
|
| Total Unusual Items |
|
-0.83
+49.67%
|
-1.66
-620.43%
|
-0.23
-104.76%
|
4.84
|
| Total Unusual Items Excluding Goodwill |
|
-0.83
+49.67%
|
-1.66
-620.43%
|
-0.23
-104.76%
|
4.84
|
| Special Income Charges |
|
—
|
—
|
-0.25
-105.46%
|
4.58
|
| Other Special Charges |
|
—
|
—
|
0.25
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.00
+100.00%
|
-4.58
|
| Net Income |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Pretax Income |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Net Non Operating Interest Income Expense |
|
-0.66
-254.30%
|
-0.19
-149.73%
|
0.37
+50.20%
|
0.25
|
| Interest Expense Non Operating |
|
0.67
+191.74%
|
0.23
+91.67%
|
0.12
|
0.00
|
| Net Interest Income |
|
-0.66
-254.30%
|
-0.19
-149.73%
|
0.37
+50.20%
|
0.25
|
| Interest Expense |
|
0.67
+191.74%
|
0.23
+91.67%
|
0.12
|
0.00
|
| Interest Income Non Operating |
|
0.01
-72.73%
|
0.04
-91.09%
|
0.49
+98.39%
|
0.25
|
| Interest Income |
|
0.01
-72.73%
|
0.04
-91.09%
|
0.49
+98.39%
|
0.25
|
| Other Income Expense |
|
-11.74
-82.34%
|
-6.44
-119.20%
|
-2.94
-167.80%
|
4.33
|
| Other Non Operating Income Expenses |
|
-10.87
-127.36%
|
-4.78
-76.62%
|
-2.71
-436.04%
|
-0.51
|
| Gain On Sale Of Security |
|
-0.83
+49.67%
|
-1.66
-8385.00%
|
0.02
-92.16%
|
0.26
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Net Income From Continuing Operation Net Minority Interest |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Net Income From Continuing And Discontinued Operation |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Net Income Continuous Operations |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Normalized Income |
|
-27.79
-18.40%
|
-23.47
+21.56%
|
-29.92
+32.90%
|
-44.59
|
| Net Income Common Stockholders |
|
-28.62
-13.91%
|
-25.13
+16.69%
|
-30.16
+24.14%
|
-39.75
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Diluted EPS |
|
—
|
-2.36
+40.70%
|
-3.98
+34.75%
|
-6.10
|
| Basic EPS |
|
—
|
-2.36
+40.70%
|
-3.98
+34.75%
|
-6.10
|
| Basic Average Shares |
|
—
|
10.64
+40.50%
|
7.58
+15.20%
|
6.58
|
| Diluted Average Shares |
|
—
|
10.64
+40.50%
|
7.58
+15.20%
|
6.58
|
| Diluted NI Availto Com Stockholders |
|
-28.62
-13.91%
|
-25.13
+16.69%
|
-30.16
+24.14%
|
-39.75
|
| Depreciation Amortization Depletion Income Statement |
|
0.07
+1300.00%
|
0.01
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.07
+1300.00%
|
0.01
|
—
|
—
|
| Earnings From Equity Interest |
|
-0.04
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
12.96
+254.86%
|
3.65
-50.09%
|
7.32
-71.66%
|
25.82
|
| Current Assets |
|
8.89
+169.29%
|
3.30
-52.03%
|
6.88
-73.31%
|
25.80
|
| Cash Cash Equivalents And Short Term Investments |
|
7.80
+440.33%
|
1.44
-68.60%
|
4.59
-77.09%
|
20.05
|
| Cash And Cash Equivalents |
|
7.80
+440.33%
|
1.44
-68.60%
|
4.59
-77.09%
|
20.05
|
| Cash Financial |
|
—
|
—
|
—
|
20.05
|
| Receivables |
|
0.16
|
0.00
-100.00%
|
0.01
-14.29%
|
0.01
|
| Accounts Receivable |
|
0.16
|
0.00
|
—
|
—
|
| Other Receivables |
|
—
|
—
|
0.01
-14.29%
|
0.01
|
| Prepaid Assets |
|
0.93
-49.76%
|
1.86
-18.57%
|
2.28
-60.18%
|
5.73
|
| Total Non Current Assets |
|
4.06
+1064.47%
|
0.35
-19.03%
|
0.43
+1952.38%
|
0.02
|
| Net PPE |
|
0.70
+6860.00%
|
0.01
|
—
|
—
|
| Gross PPE |
|
0.70
+6860.00%
|
0.01
|
—
|
—
|
| Other Properties |
|
0.70
+6860.00%
|
0.01
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
2.72
|
0.00
|
—
|
—
|
| Goodwill |
|
1.79
|
0.00
|
—
|
—
|
| Other Intangible Assets |
|
0.93
|
—
|
—
|
—
|
| Investments And Advances |
|
0.40
|
0.00
|
—
|
—
|
| Long Term Equity Investment |
|
0.40
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
0.25
-25.37%
|
0.34
-21.35%
|
0.43
+1952.38%
|
0.02
|
| Total Liabilities Net Minority Interest |
|
28.89
+7.51%
|
26.87
+41.09%
|
19.05
+3.48%
|
18.41
|
| Current Liabilities |
|
28.58
+30.71%
|
21.86
+14.78%
|
19.05
+22.22%
|
15.59
|
| Payables And Accrued Expenses |
|
9.95
+6.27%
|
9.37
+3.66%
|
9.04
+15.17%
|
7.84
|
| Payables |
|
4.27
+3.39%
|
4.13
-10.84%
|
4.63
+123.12%
|
2.08
|
| Accounts Payable |
|
4.27
+3.39%
|
4.13
-10.84%
|
4.63
+123.12%
|
2.08
|
| Current Accrued Expenses |
|
5.68
+8.54%
|
5.24
+18.92%
|
4.40
-23.68%
|
5.77
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.50
-14.04%
|
0.58
-30.90%
|
0.83
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.32
-79.82%
|
1.57
-82.91%
|
9.16
+18.93%
|
7.70
|
| Current Debt |
|
—
|
1.57
-82.91%
|
9.16
+18.93%
|
7.70
|
| Other Current Borrowings |
|
—
|
1.57
-82.91%
|
9.16
+18.93%
|
7.70
|
| Current Capital Lease Obligation |
|
0.32
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
12.30
+118.19%
|
5.64
+33070.59%
|
0.02
-54.05%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.32
-93.71%
|
5.01
|
0.00
-100.00%
|
2.82
|
| Long Term Debt And Capital Lease Obligation |
|
0.32
-93.71%
|
5.01
|
—
|
2.82
|
| Long Term Debt |
|
—
|
5.01
|
—
|
2.82
|
| Long Term Capital Lease Obligation |
|
0.32
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
-15.94
+31.37%
|
-23.22
-97.93%
|
-11.73
-258.36%
|
7.41
|
| Common Stock Equity |
|
-15.94
+31.37%
|
-23.22
-97.88%
|
-11.74
-258.40%
|
7.41
|
| Capital Stock |
|
0.03
+113.33%
|
0.01
+36.36%
|
0.01
-83.58%
|
0.07
|
| Common Stock |
|
0.03
+113.33%
|
0.01
+87.50%
|
0.01
-88.06%
|
0.07
|
| Preferred Stock |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Share Issued |
|
31.73
+117.48%
|
14.59
+73.87%
|
8.39
+26.30%
|
6.64
|
| Ordinary Shares Number |
|
31.73
+117.48%
|
14.59
+73.87%
|
8.39
+26.30%
|
6.64
|
| Additional Paid In Capital |
|
290.93
+14.07%
|
255.03
+5.65%
|
241.41
+4.80%
|
230.34
|
| Retained Earnings |
|
-306.89
-10.29%
|
-278.27
-9.93%
|
-253.15
-13.52%
|
-223.00
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Other Equity Adjustments |
|
—
|
—
|
-0.00
|
—
|
| Total Equity Gross Minority Interest |
|
-15.94
+31.37%
|
-23.22
-97.93%
|
-11.73
-258.36%
|
7.41
|
| Total Capitalization |
|
-15.94
+12.49%
|
-18.21
-55.22%
|
-11.73
-214.68%
|
10.23
|
| Working Capital |
|
-19.69
-6.06%
|
-18.56
-52.59%
|
-12.16
-219.14%
|
10.21
|
| Invested Capital |
|
-15.94
+4.26%
|
-16.65
-546.45%
|
-2.58
-114.36%
|
17.93
|
| Total Debt |
|
0.63
-90.41%
|
6.58
-28.21%
|
9.16
-12.96%
|
10.53
|
| Net Debt |
|
—
|
5.13
+12.44%
|
4.57
|
—
|
| Capital Lease Obligations |
|
0.63
|
0.00
|
—
|
—
|
| Net Tangible Assets |
|
-18.66
+19.67%
|
-23.22
-97.93%
|
-11.73
-258.36%
|
7.41
|
| Tangible Book Value |
|
-18.66
+19.67%
|
-23.22
-97.88%
|
-11.74
-258.40%
|
7.41
|
| Current Notes Payable |
|
—
|
—
|
—
|
0.00
|
| Current Provisions |
|
5.51
+16.84%
|
4.71
|
—
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-14.11
-32.67%
|
-10.64
+50.88%
|
-21.66
+45.52%
|
-39.76
|
| Cash Flow From Continuing Operating Activities |
|
-14.11
-32.67%
|
-10.64
+50.88%
|
-21.66
+45.52%
|
-39.76
|
| Net Income From Continuing Operations |
|
-28.62
-13.91%
|
-25.13
+16.66%
|
-30.15
+24.16%
|
-39.75
|
| Depreciation Amortization Depletion |
|
0.14
+2760.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.00
|
| Depreciation |
|
0.14
+2760.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.00
|
| Depreciation And Amortization |
|
0.14
+2760.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.00
|
| Other Non Cash Items |
|
5.62
-2.63%
|
5.77
+95.20%
|
2.96
+172.53%
|
-4.08
|
| Stock Based Compensation |
|
0.23
-53.09%
|
0.49
+25.58%
|
0.39
-89.33%
|
3.63
|
| Provisionand Write Offof Assets |
|
0.04
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
7.07
+140.89%
|
2.94
+14775.00%
|
-0.02
+92.16%
|
-0.26
|
| Gain Loss On Investment Securities |
|
-0.44
-126.74%
|
1.66
+8385.00%
|
-0.02
+92.16%
|
-0.26
|
| Change In Working Capital |
|
1.41
-73.37%
|
5.29
+2.46%
|
5.16
+638.77%
|
0.70
|
| Change In Receivables |
|
0.05
|
0.00
|
—
|
0.00
|
| Changes In Account Receivables |
|
0.05
|
0.00
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.86
+71.97%
|
0.50
-83.45%
|
3.04
+581.01%
|
-0.63
|
| Change In Payables And Accrued Expense |
|
0.61
-87.18%
|
4.79
+125.42%
|
2.12
+59.58%
|
1.33
|
| Change In Accrued Expense |
|
0.50
-94.99%
|
10.01
+1984.18%
|
-0.53
-118.05%
|
2.94
|
| Change In Payable |
|
0.11
+102.17%
|
-5.22
-296.50%
|
2.65
+264.80%
|
-1.61
|
| Change In Account Payable |
|
0.11
+102.17%
|
-5.22
-296.50%
|
2.65
+264.80%
|
-1.61
|
| Change In Other Current Liabilities |
|
-0.12
|
0.00
|
—
|
—
|
| Investing Cash Flow |
|
-2.81
|
0.00
+100.00%
|
-0.00
+70.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-2.81
|
0.00
+100.00%
|
-0.00
+70.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.00
+70.00%
|
-0.01
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.00
+70.00%
|
-0.01
|
| Capital Expenditure |
|
—
|
—
|
-0.00
+70.00%
|
-0.01
|
| Net Investment Purchase And Sale |
|
-0.43
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-0.43
|
0.00
|
—
|
—
|
| Net Business Purchase And Sale |
|
-2.38
|
0.00
|
—
|
—
|
| Purchase Of Business |
|
-2.38
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
23.28
+210.97%
|
7.49
+20.71%
|
6.20
-80.75%
|
32.21
|
| Cash Flow From Continuing Financing Activities |
|
23.28
+210.97%
|
7.49
+20.71%
|
6.20
-80.75%
|
32.21
|
| Net Issuance Payments Of Debt |
|
4.68
+412.77%
|
-1.50
+51.62%
|
-3.09
-132.54%
|
9.50
|
| Issuance Of Debt |
|
5.23
-26.16%
|
7.08
+650.69%
|
0.94
-90.59%
|
10.02
|
| Repayment Of Debt |
|
-0.55
+93.61%
|
-8.57
-112.52%
|
-4.04
-678.96%
|
-0.52
|
| Long Term Debt Issuance |
|
5.23
-26.16%
|
7.08
+650.69%
|
0.94
-90.59%
|
10.02
|
| Long Term Debt Payments |
|
-0.55
+93.61%
|
-8.57
-112.52%
|
-4.04
-678.96%
|
-0.52
|
| Net Long Term Debt Issuance |
|
4.68
+412.77%
|
-1.50
+51.62%
|
-3.09
-132.54%
|
9.50
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
-0.52
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
-0.52
|
| Net Common Stock Issuance |
|
15.86
+168.31%
|
5.91
-27.22%
|
8.12
-64.22%
|
22.70
|
| Proceeds From Stock Option Exercised |
|
3.09
-22.16%
|
3.97
|
0.00
-100.00%
|
0.01
|
| Net Other Financing Charges |
|
-0.35
+60.94%
|
-0.90
|
—
|
—
|
| Changes In Cash |
|
6.35
+301.59%
|
-3.15
+79.61%
|
-15.46
-104.73%
|
-7.55
|
| Beginning Cash Position |
|
1.44
-68.60%
|
4.59
-77.09%
|
20.05
-27.35%
|
27.61
|
| End Cash Position |
|
7.80
+440.33%
|
1.44
-68.60%
|
4.59
-77.09%
|
20.05
|
| Free Cash Flow |
|
-14.11
-32.67%
|
-10.64
+50.89%
|
-21.66
+45.53%
|
-39.77
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.37
-57.74%
|
0.89
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
15.86
+168.31%
|
5.91
-27.22%
|
8.12
-64.22%
|
22.70
|
| Earnings Losses From Equity Investments |
|
0.04
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
15.86
+168.31%
|
5.91
-36.39%
|
9.29
-59.07%
|
22.70
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
1.17
|
0.00
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
1.17
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-24 View
- 10-K2026-03-23 View
- 42026-02-17 View
- 8-K2026-02-17 View
- 8-K2026-02-17 View
- 8-K2026-02-02 View
- 8-K2026-01-16 View
- 8-K2025-12-29 View
- 8-K2025-11-26 View
- 10-Q2025-11-14 View
- 8-K2025-10-23 View
- 8-K2025-09-26 View
- 8-K2025-09-12 View
- 42025-09-10 View
- 42025-09-10 View
- 42025-09-10 View
- 42025-09-10 View
- 8-K2025-09-08 View
- 8-K2025-08-18 View
- 10-Q2025-08-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|